Yesterday was an incredibly tough day for financial markets around the world. As Greece moves closer and closer to the deadline to avert a default, investors around the world eagerly anticipated the solution. While there still has yet to be a solution to the crisis, US stocks are up slightly today. Investors believe that if the crisis continues, the Federal Reserve will delay increasing their interest rate; leading to positive investor sentiment overall. This opens the door for positive opportunities. Here are some of the best opportunities in biotech today.
Synergy Pharmaceuticals Starts To Edge Up
Synergy Pharmaceuticals Inc (NASDAQ: SGYP)
Synergy Pharmaceuticals has been a relatively interesting stock to watch recently. About two weeks ago, the company released results with regard to a recent plecanatide study; showing that the experimental drug has the potential to do great things. As a result, the stock climbed. Following the climb, there was a bit of a correction; followed by declines from the Greek debt crisis. However, I don’t think that these declines are likely to be long lasting. As plecanatide moves to the next step in studies, SGYP becomes more and more valuable. The bottom line here is that we’re talking about a great company with strong management and what appears to be a strong product. Therefore, SGYP is likely to climb. Thanks to yesterday’s declines, investors have the ability to get in on the gains at a low cost.
MannKind Corporation Is Getting Closer To Long Term Gains
MannKind Corporation (NASDAQ: MNKD)
MannKind stock is also edging up slightly today with the hopes that the Federal Reserve will delay an interest rate hike. However, that’s not the only reason that I believe MNKD is likely to grow. As a matter of fact, if you follow my writing here or elsewhere, you know that I have an incredibly bullish opinion of the stock. The reality is that the bears got hold of this one after the pre-launch of Afrezza went slower than expected. However, I think those bears are going to be in for a big surprise. Soon, Afrezza will be pushed into the Direct-to-Consumer campaign. Considering conversations I’ve had with diabetics that knew nothing about Afrezza, I’m expecting the Direct-to-consumer campaign to yield overwhelmingly positive results; which will likely push MNKD up in the market. So, keep a close eye on this one because massive growth is just around the corner.
Gilead Sciences Deserves A Better Valuation
Gilead Sciences, Inc. (NASDAQ: GILD)
Finally, we have Gilead Sciences. In my opinion, Gilead Sciences isn’t only one of the strongest companies in biotech today, it’s one of the biggest opportunities. GILD has taken control of the HIV and HCV markets; however, their stock price hasn’t grown like you would expect. As AbbVie made its way into the HCV market, investors got spooked; refusing to send the stock much higher. However, in the mean time, the profits realized by GILD have grown; bringing the P/E ratio down incredibly. Currently, the stock is trading with a P/E ratio under 10! This means that GILD is far undervalued; and thanks to yesterday’s declines, the stock became even cheaper. However, this one is likely to grow big in the long run. As more positive earnings reports are released, we’re likely to see nice gains. So, this is definitely one to watch.
Do You Know Of Any Others?
Do you know of any other stocks in biotech that are producing strong opportunities? If so, let us know in the comments below!